Combining BRAF inhibitor and anti PD-L1 antibody dramatically improves tumor regression and anti tumor immunity in an immunocompetent murine model of anaplastic thyroid cancer

The interaction of programmed cell death-1 and its ligand is widely studied in cancer. Monoclonal antibodies blocking these molecules have had great success but little is known about them in thyroid cancer. We investigated the role of PD-L1 in thyroid cancer with respect to BRAF mutation and MAP kin...

Descripción completa

Detalles Bibliográficos
Autores principales: Brauner, Eran, Gunda, Viswanath, Borre, Pierre Vanden, Zurakowski, David, Kim, Yon Seon, Dennett, Kate Virginia, Amin, Salma, Freeman, Gordon James, Parangi, Sareh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4941380/
https://www.ncbi.nlm.nih.gov/pubmed/26943572
http://dx.doi.org/10.18632/oncotarget.7839

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4941380/
https://www.ncbi.nlm.nih.gov/pubmed/26943572
http://dx.doi.org/10.18632/oncotarget.7839

Ejemplares similares